DEVELOPMENT OF A MODEL TO ASSESS THE COST-EFFECTIVENESS OF THERAPIES FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) FOLLOWING A REFERENCE MODEL FRAMEWORK

被引：0
|
作者：
Aguiar-Ibanez, R. [1 ]
Palencia, R. [2 ]
Kandaswamy, P. [3 ]
Flavin, J. [4 ]
Gauthier, A. [5 ]
Davies, M. J. [6 ]
机构：
[1] Amaris Consulting Uk, London, England
[2] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[3] Boehringer Ingelheim Uk, Bracknell, Berks, England
[4] Boehringer Ingelheim Canada Ltd, Burlingon, ON, Canada
[5] Amaris, London, England
[6] Univ Leicester, Leicester, Leics, England
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.1859
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRM107
引用
收藏
页码：A562 / A562
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF SAXAGLIPTIN COMPARED TO SITAGLIPTIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Hutchings, A.
    Tolley, K.
    Achana, F.
    Brereton, N. J.
    Lebmeier, M.
    Mesa, O. A.
    VALUE IN HEALTH, 2011, 14 (07) : A478 - A478
  • [2] ASSESSING THE INFLUENCE OF INCORPORATING SECONDARY CARDIOVASCULAR EVENTS INTO A TYPE 2 DIABETES MELLITUS (T2DM) COST-EFFECTIVENESS MODEL
    McEwan, P.
    Evans, L. M.
    Bergenheim, K.
    VALUE IN HEALTH, 2010, 13 (07) : A293 - A293
  • [3] IMPACT OF PATIENT WEIGHT TRAJECTORY ON COST-EFFECTIVENESS OF TREATMENTS OF TYPE 2 DIABETES MELLITUS (T2DM)
    Schroeder, M.
    Willis, M.
    Johansen, P.
    Girod, I
    Neslusan, C.
    Thompson, G.
    VALUE IN HEALTH, 2013, 16 (07) : A440 - A440
  • [4] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN COMBINATION WITH INSULIN FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN SPAIN
    Sanchez-Covisa, J.
    Capel, M.
    Schmidt, R.
    Charokopou, M.
    Verheggen, B. G.
    VALUE IN HEALTH, 2014, 17 (07) : A350 - A350
  • [5] THE EFFECT OF TREATMENT INTENSIFICATION ASSUMPTIONS ON ESTIMATES OF COST-EFFECTIVENESS IN TYPE 2 DIABETES MELLITUS (T2DM)
    Willis, M.
    Johansen, P.
    Neslusan, C.
    VALUE IN HEALTH, 2015, 18 (03) : A62 - A62
  • [6] THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS SULFONYLUREA (SU) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN GERMANY
    Erhardt, W.
    Bergenheim, K.
    Townsend, R.
    Puelles, Fernandez de Troconiz J.
    McEwan, P.
    VALUE IN HEALTH, 2010, 13 (07) : A291 - A292
  • [7] SYSTEMATIC REVIEW OF COST EFFECTIVENESS OF DAPAGLIFLOZIN TREATING PATIENTS OF TYPE 2 DIABETES MELLITUS (T2DM)
    Hu, C.
    Zhang, C.
    Wang, B.
    Xu, L.
    VALUE IN HEALTH, 2018, 21 : S39 - S39
  • [8] THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS NPH INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN POLAND
    Kolasa, K.
    Niewada, M.
    de Troconiz, J. Puelles Fernandez
    Townsend, R.
    McEwan, P.
    VALUE IN HEALTH, 2010, 13 (07) : A290 - A290
  • [9] Development of a model to assess the cost-effectiveness of gestational diabetes mellitus screening and lifestyle change for the prevention of type 2 diabetes mellitus
    Lohse, Nicolai
    Marseille, Elliot
    Kahn, James G.
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2011, 115 : S20 - S25
  • [10] THE IMPORTANCE OF HBA1C EVOLUTION IN COST-EFFECTIVENESS MODELING OF TYPE 2 DIABETES MELLITUS (T2DM)
    Willis, M.
    He, J.
    Neslusan, C.
    Johansen, P.
    Worbes-cerezo, M.
    VALUE IN HEALTH, 2012, 15 (07) : A500 - A500
12345